All In Biotech

Drug Trial Radar · NCT05955365

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation

Monotherapy With a P2Y12 Inhibitor Followed by a Direct-acting Oral Anticoagulant in Patients With ATRial fIbrillation Undergoing Drug-eluting Stent Implantation

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,010 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,010

Planned (sponsor's estimate)

Start

Dec 18, 2023

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sahajanand Medical Technologies Limited
First posted
Jul 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined. The currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by treatment with two of these medications for up to 6-12 months after stent implantation. Thereafter, patients usually receive long-term treatment with only one drug, an anticoagulant. In the monotherapy group of this study, the investigators will investigate a strategy where only one antithrombotic drug will be used at a time. During the first month after stent implantation, the investigators will prescribe an antiplatelet medication, followed by an oral anticoagulant as monotherapy. This strategy might be associated with fewer bleeding complications, while protecting adequately against thrombotic events. In this study the investigators would like to investigate whether treatment with a single antithrombotic drug ("monotherapy strategy") is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications ("standard-of-care strategy").

Conditions

  • Percutaneous Coronary Intervention (PCI)
  • Atrial Fibrillation (AF)
  • Oral Anticoagulation
  • P2Y12 Inhibitor

Interventions

  • P2Y12 inhibitorDrug

    The choice of P2Y12 inhibitor is left at investigator's discretion.

  • AspirinDrug

    Aspirin is administered for up to 1 month after PCI at investigator's discretion

  • DOACDrug

    The choice of DOAC is left at investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of participants with a major adverse cardiac or cerebral events (MACCE), defined as the composite of death from any cause, myocardial infarction, stroke or non-central nervous system (non-CNS) systemic embolismTime frame: 12 months
  2. The number of participants with a major or clinically relevant non-major bleeding (MCB), defined according to the International Society of Thrombosis and Haemostasis (ISTH) criteriaTime frame: 12 months

Locations

18 sites in 9 countries. Site status is shown where the registry gives one.

  • Hartcentrum Hasselt

    Hasselt, Belgium · Recruiting

  • CHU Nîmes

    Nîmes, France · Recruiting

  • Universitätsklinikum Frankfurt/Main

    Frankfurt am Main, Germany · Recruiting

  • Klinikum Friedrichshafen

    Friedrichshafen, Germany · Withdrawn

  • Ospedale Ferrarotto

    Catania, Catania CT, Italy · Recruiting

  • IRCCS Humanitas

    Milan, Rozzano, Italy · Recruiting

  • UMC public

    Amsterdam, Netherlands · Recruiting

  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

    Poznan, Poland · Withdrawn

  • Hospital Universitario Marques de Valdecilla

    Santander, Spain · Recruiting

  • Universitätsspital Basel

    Basel, Switzerland · Recruiting

  • Inselspital, Bern University Hospital, Department of Cardiology

    Bern, Switzerland · Recruiting

  • Hôpitaux Universitaires de Genève

    Geneva, Switzerland · Recruiting

  • HOCH Health Ostschweiz, Kantonsspital St.Gallen

    Sankt Gallen, Switzerland · Recruiting

  • University Hospital Zürich

    Zurich, Switzerland · Recruiting

  • Kantonsspital Baselland Liestal

    Liestal, Basel-Landschaft, Switzerland · Recruiting

  • Kantonsspital Aarau

    Aarau, Canton of Aargau, Switzerland · Recruiting

  • Cardiocentro Ticino Institute

    Lugano, Canton Ticino, Switzerland · Recruiting

  • Imperial College London

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.